Votrient (pazopanib) for Gastrointenstinal Stromal Tumors (GIST)
Pazopanib(Votrient) is a new drug that is approved for kidney cancer and acts in ways that may be effective in GIST. These are important pathways for GIST tumors and several trials are avaluating this drug in GIST, including: Efficacy of Pazopanib in Gastrointestinal Stromal Tumors (GIST), NCT Number: NCT01323400, Pazopanib in Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors (GIST) NCT Number: NCT01391611 and Pazopanib in Advanced
Read more